Long-term management of pediatric psoriasis with ixekizumab: a case report.

New-onset and flares of psoriasis after COVID-19 infection or vaccination successfully treated with biologics: a case series.

Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study.

Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience.

Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers.

Effectiveness and safety of anti-IL-23 and anti-IL-17 biological therapies for psoriasis in elderly patients: Real-world experience from two Italian hospitals.

Safety of anti-IL-23 drugs in patients with moderate-to-severe plaque psoriasis and previous tuberculosis infection: a monocentric retrospective study.

Upadacitinib for the treatment of atopic dermatitis in the elderly: an Italian case series of seven patients.

Adalimumab-induced paradoxical pustular psoriasis and alopecia successfully treated with ixekizumab in a patient affected by hidradenitis suppurativa.

Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience.